דוסיטקסל טבע ® 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

DOCETAXEL 27.73 MG / 1 ML

Mevcut itibaren:

ABIC MARKETING LTD

ATC kodu:

L01CD02

Farmasötik formu:

CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

Uygulama yolu:

I.V

Tarafından üretildi:

PHARMACHEMIE B.V., THE NETHERLANDS

Terapötik grubu:

DOCETAXEL

Terapötik endikasyonlar:

Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have inclu

Yetkilendirme tarihi:

2011-06-01